Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GYRENASDAQ:MLYSNASDAQ:RNACNASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$8.68-22.6%$9.00$6.11▼$19.00$813.82M1.9105,046 shs2.11 million shsMLYSMineralys Therapeutics$15.96-2.2%$14.49$8.24▼$18.38$1.04B-0.3487,363 shs927,902 shsRNACCartesian Therapeutics$9.16+0.1%$11.69$8.85▼$41.87$237.74M0.51115,218 shs53,651 shsWVEWave Life Sciences$5.95-2.3%$7.01$4.25▼$16.74$917.10M-0.921.29 million shs1.01 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics-22.57%-23.52%-5.55%-24.78%-35.89%MLYSMineralys Therapeutics-2.21%+3.97%+17.96%+66.95%+27.48%RNACCartesian Therapeutics+0.11%-10.72%-21.24%-52.39%-64.02%WVEWave Life Sciences-2.30%-6.00%-12.37%-46.54%-7.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGYREGyre Therapeutics0.3791 of 5 stars0.02.00.00.02.41.70.0MLYSMineralys Therapeutics2.9062 of 5 stars3.51.00.00.04.05.00.0RNACCartesian Therapeutics1.5224 of 5 stars3.40.00.00.01.93.30.0WVEWave Life Sciences4.2887 of 5 stars3.51.00.04.83.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre Therapeutics 3.00BuyN/AN/AMLYSMineralys Therapeutics 3.00Buy$38.00138.10% UpsideRNACCartesian Therapeutics 2.71Moderate Buy$43.00369.43% UpsideWVEWave Life Sciences 3.00Buy$21.17255.74% UpsideCurrent Analyst Ratings BreakdownLatest RNAC, GYRE, MLYS, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/8/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.004/29/2025WVEWave Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/9/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $41.004/9/2025RNACCartesian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/8/2025WVEWave Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$18.004/2/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $42.003/26/2025WVEWave Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/14/2025RNACCartesian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $40.003/13/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$100.64M8.09$0.17 per share50.49$0.18 per share48.22MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ARNACCartesian Therapeutics$34.17M6.96N/AN/A($82.38) per share-0.11WVEWave Life Sciences$104.94M8.74N/AN/A$0.40 per share14.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics-$92.93M$0.02434.00∞N/A-84.57%-118.43%-71.97%8/12/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)RNACCartesian Therapeutics-$219.71M-$52.83N/AN/AN/A-510.72%N/A-6.03%N/AWVEWave Life Sciences-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%N/ALatest RNAC, GYRE, MLYS, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/8/2025Q1 2025RNACCartesian Therapeutics-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 million5/8/2025Q1 2025WVEWave Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 million3/4/2025Q4 2024WVEWave Life Sciences-$0.17$0.17+$0.34$0.17$25.60 million$83.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/AWVEWave Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A3.723.29MLYSMineralys TherapeuticsN/A14.0214.02RNACCartesian TherapeuticsN/A10.7010.70WVEWave Life SciencesN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%MLYSMineralys Therapeutics84.46%RNACCartesian Therapeutics86.95%WVEWave Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics19.52%MLYSMineralys Therapeutics25.56%RNACCartesian Therapeutics57.90%WVEWave Life Sciences29.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics4093.76 million75.27 millionNo DataMLYSMineralys Therapeutics2865.18 million33.27 millionOptionableRNACCartesian Therapeutics6425.95 million10.70 millionOptionableWVEWave Life Sciences240154.13 million108.14 millionOptionableRNAC, GYRE, MLYS, and WVE HeadlinesRecent News About These CompaniesBNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 20, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives $21.17 Consensus PT from BrokeragesMay 20, 2025 | americanbankingnews.comWave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust CorpMay 19, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Buy" by AnalystsMay 19, 2025 | marketbeat.comPolar Asset Management Partners Inc. Has $6.89 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 18, 2025 | marketbeat.comPolar Capital Holdings Plc Acquires New Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 18, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by D. E. Shaw & Co. Inc.May 17, 2025 | marketbeat.comMPM Bioimpact LLC Raises Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)May 16, 2025 | marketbeat.comFY2025 EPS Estimates for WVE Increased by Cantor FitzgeraldMay 16, 2025 | marketbeat.comFY2025 Earnings Estimate for WVE Issued By Cantor FitzgeraldMay 16, 2025 | americanbankingnews.comMaven Securities LTD Sells 680,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)May 15, 2025 | marketbeat.comB. Riley Has Pessimistic Outlook of WVE FY2029 EarningsMay 14, 2025 | marketbeat.comFY2028 Earnings Estimate for WVE Issued By WedbushMay 14, 2025 | marketbeat.comIs Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?May 13, 2025 | msn.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by The Manufacturers Life Insurance CompanyMay 13, 2025 | marketbeat.comAlgert Global LLC Invests $527,000 in Wave Life Sciences Ltd. (NASDAQ:WVE)May 13, 2025 | marketbeat.comDriehaus Capital Management LLC Raises Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 10, 2025 | marketbeat.comWave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comWAVE Life Sciences Ltd (WVE) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 9, 2025 | finance.yahoo.comWAVE Life Sciences Ltd (WVE) Q1 2025 Earnings Call Highlights: Clinical Advancements and ...May 9, 2025 | finance.yahoo.comVoya Investment Management LLC Boosts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNAC, GYRE, MLYS, and WVE Company DescriptionsGyre Therapeutics NASDAQ:GYRE$8.68 -2.53 (-22.57%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.98 +0.30 (+3.50%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Mineralys Therapeutics NASDAQ:MLYS$15.96 -0.36 (-2.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$15.97 +0.01 (+0.06%) As of 05/23/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Cartesian Therapeutics NASDAQ:RNAC$9.16 +0.01 (+0.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.11 -0.05 (-0.55%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Wave Life Sciences NASDAQ:WVE$5.95 -0.14 (-2.30%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.10 +0.16 (+2.61%) As of 05/23/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
